Bristol Myers Squibb (CELG-RI) EBITDA (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported EBITDA for 18 consecutive years, with $360.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 122.51% year-over-year to $360.0 million in Q2 2026; TTM through Jun 2026 was -$2.8 billion, a 63.45% increase from a year earlier, with the FY2025 full-year figure at -$4.6 billion, up 79.38% from the prior year.
• EBITDA was $360.0 million for Q2 2026 at Bristol Myers Squibb, up from -$182.0 million in the prior quarter.
• Over five years, EBITDA peaked at $360.0 million in Q2 2026 and troughed at -$14.4 billion in Q1 2024.
• A 5-year average of -$1.7 billion and a median of -$773.0 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 126.02% in 2023 and plunged 7182.35% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$734.0 million in 2022, then tumbled by 45.91% to -$1.1 billion in 2023, then slumped by 332.96% to -$4.6 billion in 2024, then jumped by 43.35% to -$2.6 billion in 2025, then surged by 113.7% to $360.0 million in 2026.
• The last three EBITDA figures came in at $360.0 million (Q2 2026), -$182.0 million (Q1 2026), and -$2.6 billion (Q4 2025), per Business Quant data.